A Phase 2 interventional study of Netarsudil ophthalmic solution 0.02% and Netarsudil Ophthalmic Solution Vehicle in Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-17.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 16th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 2, and was the 6th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Brett King · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Center for Sight Las Vegas · Sites in United States
Ages 40+
By country, each count listing its studies:
netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2016.
This study's enrollment of 12 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 85 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 105th largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2016, is one of 33 in phase 2, and was the 113th registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
2 of the studies testing netarsudil in Glaucoma, Open-Angle that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07048886Center for Sight Las VegasRocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | 2026-12-31 |
| NCT07325240Mayo Clinic24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, from their registry updates:
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
This study's enrollment of 12 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
First submitted before Aerie Pharmaceuticals became part of Alcon.
Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop in each eye (OU) daily
Drug: Netarsudil ophthalmic solution 0.02%
1 drop in each eye (OU) daily
Other: Netarsudil Ophthalmic Solution Vehicle
Once daily in both eyes (OU) in the evening (PM) for 7 days
Also known as: AR-13324
Once daily in both eyes (OU) in the evening (PM) for 7 days
Change in Intraocular Pressure (IOP) Over Nocturnal Time Period
The primary efficacy endpoint was the mean change from baseline in mean nocturnal IOP (defined as the mean of the 4 nocturnal time points: 21:00, 00:00, 03:00, and 06:00 hours) on Day 8/Day 9
Time frame: Assessed over 24 hours at 9 pm, midnight, 3 am and 6 am on days 1/2 and 8/9
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame: 7 days (day 1/2 to day 8/9)
| Milestone | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution Vehicle |
|---|---|---|
| Started | 8 | 4 |
| Completed | 8 | 4 |
| Not completed | 0 | 0 |
The primary efficacy endpoint was the mean change from baseline in mean nocturnal IOP (defined as the mean of the 4 nocturnal time points: 21:00, 00:00, 03:00, and 06:00 hours) on Day 8/Day 9
| mmHg | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution Vehicle |
|---|---|---|
| Baseline (Day 1/2); nocturnal mean | 22.84 ± 2.21 | 23.56 ± 1.94 |
| Visit 4 (Day 8/9); nocturnal mean | 19.38 ± 2.86 | 23.19 ± 1.95 |
| Participants | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution Vehicle |
|---|---|---|
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | 0 | 0 |
Collected over Adverse event data was collected over 7 days from day 1/2 to day 8/9.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Netarsudil Ophthalmic Solution 0.02% | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Netarsudil Ophthalmic Solution Vehicle | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
ITT
| Age, Continuous(years) | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Mean | 64.4 ± 10.23 | 64.5 ± 5.07 | 64.4 ± 8.58 |
| Sex: Female, Male(Participants) | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Female | 4 | 2 | 6 |
| Male | 4 | 2 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 7 | 3 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Netarsudil Ophthalmic Solution 0.02% | Netarsudil Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 9 |
| White | 2 | 1 | 3 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: No
The record gives a start of Jul 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 1 year 7 months after primary completion. A results delay was requested in Sep 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil